Literature DB >> 28699283

Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study.

Charlotte F J van Tuijn1, Marein Schimmel1, Eduard J van Beers2, Erfan Nur1, Bart J Biemond1.   

Abstract

Organ damage in sickle cell disease (SCD) is a crucial determinant for disease severity and prognosis. In a previous study, we analyzed the prevalence of SCD-related organ damage and complications in adult sickle cell patients. We now describe a seven-year follow-up of this cohort.All patients from the primary analysis in 2006 (n = 104), were included for follow-up. Patients were screened for SCD-related organ damage and complications (microalbuminuria, renal failure, elevated tricuspid regurgitation flow velocity (TRV) (≥2.5 m/seconds), retinopathy, iron overload, cholelithiasis, avascular osteonecrosis, leg ulcers, acute chest syndrome (ACS), stroke, priapism and admissions for vaso-occlusive crises (VOC) biannually. Upon 7 years of follow-up, progression in the prevalence of avascular osteonecrosis (from 12.5% to 20.4%), renal failure (from 6.7% to 23.4%), retinopathy (from 39.7% to 53.8%) was observed in the whole group. In HbSS/HbSβ0 -thal patients also progression in microalbuminuria (from 34% to 45%) and elevated TRV (from 40% to 48%) was observed while hardly any progression in the prevalence of cholelithiasis, priapism, stroke or chronic ulcers was seen. The proportion of patients with at least one episode of ACS increased in the group of HbSS/HbSβ0 -thal patients from 32% to 49.1%. In conclusion, 62% of the sickle cell patients in this prospective cohort study developed a new SCD-related complication in a comprehensive care setting within 7 years of follow-up. Although the hospital admission rate for VOC remained stable, multiple forms of organ damage increased substantially. These observations underline the need for continued screening for organ damage in all adult patients with SCD.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28699283     DOI: 10.1002/ajh.24855

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Morphine promotes neovascularizing retinopathy in sickle transgeneic mice.

Authors:  Kalpna Gupta; Chunsheng Chen; Gerard A Lutty; Robert P Hebbel
Journal:  Blood Adv       Date:  2019-04-09

2.  Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality.

Authors:  Vimal K Derebail; Qingning Zhou; Emily J Ciccone; Jianwen Cai; Kenneth I Ataga
Journal:  Br J Haematol       Date:  2019-06-05       Impact factor: 6.998

3.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

4.  Inhaled steroids associated with decreased macrophage markers in nonasthmatic individuals with sickle cell disease in a randomized trial.

Authors:  Arielle L Langer; Andrew Leader; Seunghee Kim-Schulze; Yelena Ginzburg; Miriam Merad; Jeffrey Glassberg
Journal:  Ann Hematol       Date:  2019-02-20       Impact factor: 3.673

5.  Decision-Making Involvement, Self-Efficacy, and Transition Readiness in Youth With Sickle Cell Disease.

Authors:  Maureen Varty; Barbara Speller-Brown; Bonnie J Wakefield; Russell D Ravert; Katherine Patterson Kelly; Lori L Popejoy
Journal:  Nurs Res       Date:  2022 Jan-Feb 01       Impact factor: 2.381

6.  A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers.

Authors:  LaTasha H Lee; LaShanta H Whisenton; Jasmine Benger; Sophie Lanzkron
Journal:  Blood Adv       Date:  2021-12-14

7.  Antibiotics for treating acute chest syndrome in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno; Jennifer M Knight-Madden
Journal:  Cochrane Database Syst Rev       Date:  2019-09-18

8.  Development and validation of the sickle cell stress scale-adult.

Authors:  Wally R Smith; Donna K McClish; Viktor E Bovbjerg; Harjot K Singh
Journal:  Eur J Haematol       Date:  2022-06-03       Impact factor: 3.674

9.  Chronic red cell exchange in sickle cell patients with iron overload may not affect mortality.

Authors:  Yi Yuan Zhou; Hollie M Reeves; LaRhonda Webb; Zamira Santiago; Robert W Maitta
Journal:  Front Med (Lausanne)       Date:  2022-09-27

10.  First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies.

Authors:  Darren Zuro; Srideshikan Sargur Madabushi; Jamison Brooks; Bihong T Chen; Janagama Goud; Amandeep Salhotra; Joo Y Song; Liliana Echavarria Parra; Antonio Pierini; James F Sanchez; Anthony Stein; Monzr Al Malki; Marcin Kortylewski; Jeffrey Y C Wong; Parham Alaei; Jerry Froelich; Guy Storme; Susanta K Hui
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-06-11       Impact factor: 7.038

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.